Likewise, there was an increase of tumour-infiltrating NK (CD49b+Nkp46+) cells which displayed increased proliferation in response to doublet RMC-4998 and RMC-4550 therapy, even though no differences between RMC-4998 and/or RMC-4550 treated tumours were observed in terms of NK cell numbers, indicating potential increased activity (Fig. 6f). This evidence concerns the gene NCR1 and neoplasm.